FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation
Authors
Keywords
Gastric adenocarcinoma, FGFR2, HER2, cMet, Tissue microarray
Journal
VIRCHOWS ARCHIV
Volume 464, Issue 2, Pages 145-156
Publisher
Springer Nature
Online
2013-12-03
DOI
10.1007/s00428-013-1517-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547
- (2013) L. Xie et al. CLINICAL CANCER RESEARCH
- Guidelines and considerations for conducting experiments using tissue microarrays
- (2013) Mohammad Ilyas et al. HISTOPATHOLOGY
- HER2/neuGene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications
- (2012) Jaclyn F. Hechtman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- FGFR2 gene amplification and clinicopathological features in gastric cancer
- (2012) K Matsumoto et al. BRITISH JOURNAL OF CANCER
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models
- (2012) J. Zhang et al. CLINICAL CANCER RESEARCH
- Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
- (2012) J. S. Logue et al. GENES & DEVELOPMENT
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma
- (2012) Eun-Jung Jung et al. HUMAN PATHOLOGY
- Prognostic value of RKIP and p-ERK in gastric cancer
- (2012) Yoshitaka Fujimori et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
- (2012) V. Guagnano et al. Cancer Discovery
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [ 18 F]FLT Uptake
- (2011) Thorsten Fuereder et al. CLINICAL CANCER RESEARCH
- Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer
- (2011) Yuji Toiyama et al. INTERNATIONAL JOURNAL OF CANCER
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts
- (2010) W.-m. Zhao et al. CLINICAL CANCER RESEARCH
- Multimodal Therapy of Gastric Cancer
- (2010) Peter Mlkvý DIGESTIVE DISEASES
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Targeting Gastric Cancer with Trastuzumab: New Clinical Practice and Innovative Developments to Overcome Resistance
- (2009) Dimitrios H. Roukos ANNALS OF SURGICAL ONCOLOGY
- Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era
- (2009) Anna D Wagner et al. CURRENT OPINION IN ONCOLOGY
- Heterogeneity and Power in Clinical Biomarker Studies
- (2009) Melania Pintilie et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
- (2008) K. Kunii et al. CANCER RESEARCH
- The Relative Distribution of Membranous and Cytoplasmic Met Is a Prognostic Indicator in Stage I and II Colon Cancer
- (2008) F. Ginty et al. CLINICAL CANCER RESEARCH
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation